

SNS COLLEGE OF ENGINEERING

Kurumbapalayam (Po), Coimbatore - 641 107

An Autonomous Institution

Accredited by NAAC – UGC with 'A' Grade Approved by AICTE, New Delhi & Affiliated to Anna University, Chennai

DEPARTMENT OF COMPUTER SCIENCE AND TECHNOLOGY

COURSE NAME : 19CS407-DATA ANALYTICS WITH R

II YEAR / IV SEMESTER

Unit II – Statistics and Prescriptive Analytics Topic : Survival Analysis





Introduction to Survival Data Analysis





Overview

- What is survival analysis?
 - Terminology and data structure
- Kaplan-Meier methods (non-parametric)
- Cox proportional hazards regression model (semi-parametric)
- Competing Risk





What is Survival Analysis

- **Time to Event:** In many studies, the primary endpoint is the time from entering a study until a subject has a particular event occurs.
- **Medical Research:**
 - Time to death
 - Time to relapse of a disease
 - Time re-hospitialization
- **Engineering**, business, etc:
 - Engineer measures the time until failure of a product or component (mean time to failure, MTTF)
 - Credit card company measures the length of time people keep using the credit card








What is Survival Analysis

- Kind of survival studies
 - Clinical trials
 - Prospective cohort studies
 - Retrospective cohort studies





Randomized Clinical Trial (RCT)








- \rightarrow Not cured
- → Cured


→Not cured



Randomized Clinical Trial (RCT)










Cohort Study (Prospective/Retrospective)







→ Disease

- → Disease-free
- → Disease

→Disease-free



Time to Event: Example


- 10 patients with squamous cell carcinoma are recruited to receive specific treatment.
- The objective is to investigate the survival probability of the patients under this treatment.
 - Event of interest: death
- They were followed up to 16 months.
 - Duration of the study: 16 months
 - Time scale: months
- Consider right censored observations.





Time to Event: Example

Survival Data - unordered










Time to Event: Example

Survival Data - ordered







| Outcor | ne summ | ary |
|--------------|---------|-----------------|
| Censored | d Event | Total |
| 3 | 7 | 10 |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| dies at 14 m | onths | |
| | | d for the whole |
| 15 16 | study p | erioa |
| | | |
| End | | |
| stud | ly | |



Censoring

- Data are typically subject to censoring when the event does not occur within the study observation time
- Survival data are characterized by incomplete observation: **Censoring.** T-test or ANOVA cannot be used because of the censored data.
- Most common is **right censoring**. Subject leaves the study before an event occurs.
 - the study ends
 - the individual withdrew from the study/lost to follow-up
 - the individual died from **other causes**
 - the individual is ineligible for research because of other reasons





Time to Event

- Non-negative, $T \ge 0$
- To correctly collect a time to event, we need:
 - An unambiguous time origin
 - A time scale (day, month, year)
 - Definition of the event of interest





6/24/2023

Example of Data Structure

| Subje ct ID | Surviv al Time | Event (0=no/1=) s) | Gende ye r | Trea (0=P t) |
|----------------|-------------------|--------------------------|-----------------------------|--------------------|
| 1 | 4 | 1 | F | 0 |
| 2 | 2 | 0 | F | 0 |
| 3 | 6 | 1 | Μ | 1 |
| 4 | 14 | 1 | F | 1 |
| 5 | 1 | 1 | Μ | 1 |
| 6 | 10 | 1 | Μ | 1 |
| 7 | 5 | 0 | F | 0 |
| 8 | 4 | 1 | Μ | 0 |
| 9 | 16 | 0 | F | 1 |
| 10 | 3 | Data | Analytics/M.Ranchana/CST/SN | ISCE |



atment Group Placebo/1=Treatmen



Survival Analysis

- Survival analysis is concerned with studying the time between entry to a study and a subsequent event.
 - Also called "time to event analysis"
- Survival analysis attempts to answer questions such as:
 - Which fraction of a population will survive past a certain time?
 - At what rate will they fail ?
 - At what rate will they present the event ?
 - How do particular factors benefit or affect the probability of survival?





Survival Analysis

Objectives

- To estimate time to event for a group of individuals.
- To compare time to event between two or more groups.
- To assess the relationship between explanatory variables and time to event.





Survival Analysis – advantages

- Why not compare mean time to event between groups using a t-test or linear regression?
 - Ignores censoring
- Why not compare proportion of events in your groups using logistic regression?
 - Ignores time
 - Ignores censoring

Survival analysis accounts for censored observations as well as time to event.





Survival Analysis – methods

- Non-parametric estimation
 - Within-group survival: **Kaplan-Meier**
 - Between-group comparison: Log-rank Test
- Semi-parametric estimation model
 - **Cox proportional hazard model** (allows **explanatory** variables)
 - Hazard: The event of interest. Usually it is believed to be harmful, e.g. death, relapse of a disease, re-hospitalization, failure of the product or part, etc
- Parametric models: Exponential, Weibull distribution, etc. (won't cover today)








Kaplan-Meier Survival Method


- Non-parametric estimate of survival probability
- Commonly used to describe survival-ship of a study population
- Intuitive graphical presentation
- Cumulative survival characteristics
- Estimation of median survival time
- Commonly used to compare two study population







Kaplan-Meier Plot







Kaplan-Meier Survival Probability

Survival Function:

$$\hat{S}_{0}(t) = \prod_{j=1}^{t} \left(1 - \frac{E_{j}}{E_{j} + S_{j}} \right)$$


Survival Probability at

1-month = 1-1/10 = 0.9

- 3-month = (1-1/10)*(1-1/8)=0.788
- 4-month = (1-1/10)*(1-1/8)*(1-2/7) = 0.56
- 1-year survival rate = 28%

Median survival time= 6 months

The K-M curve takes a step down when there is an event.







Comparison of groups-Logrank Test

- Logrank Test :
 - For comparison of survival distributions between groups
 - The groups are defined by categorical covariates. Can be more than 2 groups.
 - e.g. Therapy : treatment, placebo Gender : male, female Age group : $\leq 40, \geq 40$
- ✤ Bad performance when two survival curves are crossing.
 - The logrank test has better performance under the assumption of **proportional hazards**.


Proportional hazards: The hazard functions for any two individuals at any point in time are proportional, and does not change with time t.







Logrank Test-Example



Single- vs Double-Lung Transplantation in Patients With Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis Since the Implementation of Lung Allocation Based on Medical Need *JAMA*. 2015;313(9):936-948. doi:10.1001/jama.2015.1175



Comparison of post-transplant death and graft failure probability in IPF patients with lung transplantation

Comparison group: single transplantation vs.

double transplantation

Logrank test:

p-value < 0.001




Log-rank Test- Another example

Comparison of composite of cardiovascular death, MI, or severe recurrent ischemia in patients with acute MI:

Comparison group: Losmapimod vs. Placebo

Logrank test:

p-value =0.24



Effect of Losmapimod on Cardiovascular Outcomes in Patients With Acute MI JAMA. 2016;315(15):1591-71599



Figure 2. Kaplan-Meier Curves for the Primary End Point



- Allows for prognostic factors.
- * Explore the relationship between survival and explanatory variables.
- * Models and compares the hazards for different groups/factors (explanatory variables).
- Important assumption:
 - Survival curves with proportional hazards

(risk of an event at different time points).





Cox Regression Survival Model

 $h(t,X) = h_0 \exp(\beta X)$ $= h_0(t) \exp(\beta_1 X_1 + \beta_2 X_2 + \dots + \beta_n X_n)$ ✤ Hazard ratio:

$$\frac{h_1(t)}{h_0(t)} = \exp(\beta)$$
• Constant, does not
• Proportional haza

 $exp(\beta)$: indicates how large (small) is the hazard in one group with respect to the hazard in the reference group



ot depend on time ard over time



Cox Regression Survival Model – Example

- HIV-patients receiving 2 types of treatment.
- * The objective is to investigate the survival probability of the patients, by gender and by treatment.
 - Event of interest: death
 - Covariates: gender (male, female), treatment (new, standard)
- They are followed up to 6 years
 - Duration of the study: 6 years (72 months)
 - Time scale: months
- Consider right censored observations












Cox-Regression model: exploring covariates



✓ Curves do not cross each other✓ Proportional hazards...





Good candidates for covariates



Cox-Regression model: exploring covariates

 $h(t,X) = h_0 \exp(\beta X)$ = $h_0(t)exp(\beta_1gender+\beta_2Treatment)$ Reference group: Female, StandardTreatment ✤ Fitted model: $h(t, X) = h_0(t)exp(-0.51*Male + 0.69*NewTreatment)$

exp(0.69)=2.0

Males have larger probabilities of survival than females

exp(-0.51) = 0.6

Patients receiving new treatment having lower survival probabilities than patients with standard treatment








Cox-Regression: Example

Figure 3. Hazard Ratios for the Primary End Point in Prespecified Subgroups of Interest at 12 Weeks After Randomization

| | Total No. | No. Events, No. 12-wk Kaplan- Meler Rate, % | | | Hazard | | |
|-----------------------------|---------------|--|------------|---------|------------|---------|---------|
| Subgroup | Losmapimod | Placebo | Losmapimod | Placebo | Losmapimod | Placebo | (95% C |
| Qualifying diagnosis | | | | | | | |
| Non-ST-elevation MI | 1299 | 1325 | 111 | 90 | 8.6 | 6.8 | 1.27 (0 |
| ST-elevation MI | 432 | 433 | 28 | 33 | 6.5 | 7.6 | 0.84 (0 |
| Chronic kidney disease | | | | | | | |
| Yes | 121 | 123 | 25 | 15 | 20.7 | 12.2 | 1.73 (0 |
| No | 1609 | 1635 | 113 | 108 | 7.0 | 6.6 | 1.07 (0 |
| Prior MI | | | | | | | |
| Yes | 425 | 426 | 48 | 40 | 11.4 | 9.4 | 1.22 (0 |
| NO | 1306 | 1332 | 91 | 83 | 7.0 | 6.2 | 1.12 (0 |
| Prior PCI or CABG surgery | | | | | | | |
| Yes | 466 | 464 | 50 | 42 | 10.8 | 9.1 | 1.21 (0 |
| No | 1264 | 1294 | 88 | 81 | 7.0 | 6.3 | 1.12 (0 |
| Prior heart failure | | | | | | | |
| Yes | 206 | 216 | 28 | 21 | 13.6 | 9.8 | 1.43 (0 |
| No | 1524 | 1542 | 110 | 102 | 7.2 | 6.6 | 1.10 (0 |
| Planned treatment strateg | JY | | | | | | |
| Invasive | 1575 | 1603 | 115 | 105 | 7.3 | 6.6 | 1.12 (0 |
| Conservative | 156 | 155 | 24 | 18 | 15.4 | 11.6 | 1.34 (0 |
| No. of predictors of cardio | wascular rtsk | | | | | | |
| 0 | 40 | 40 | 3 | 2 | 7.5 | 5.0 | 1.51 (0 |
| 1 | 912 | 900 | 59 | 46 | 6.5 | 5.1 | 1.27 (0 |
| 2 | 466 | 518 | 36 | 39 | 7.8 | 7.6 | 1.03 (0 |
| ≥3 | 313 | 300 | 41 | 36 | 13.2 | 12.1 | 1.11 (0 |
| Overall | 1731 | 1758 | 139 | 123 | 8.1 | 7.0 | 1.16 (0 |
| Overall | 1731 | 1758 | 139 | 123 | 8.1 | 7.0 | |

Figure 3 (truncated) - JAMA 2016:315(15):1591-71599 Data Analytics/M.Kanchana/CST/SNSCE







Competing Risks

"Competing risks are said to be present when a patient is at risk of more than one mutually exclusive event, such as death from different causes, and the occurrence of one of these will prevent any other event from ever happening."



Gichangi & Vach (2005)



Competing Risks


Examples:

- Event of interest: Death.
- Cause of death was categorized into the following:
 - Breast cancer
 - Heart disease (CVD)
 - Other causes






Competing Risks – Example







Competing Risks – Example







Competing Risks – Data format

Data

| Patient ID | T (treatment) | Y1 (Cancer death) | Y2 (CVD death) | Time (years) |
|---------------|------------------|----------------------|-------------------|--------------|
| 1 | B | No | No | 10 |
| 2 | A | No | Yes | 4 |
| 3 | A | Yes | No | 2 |





Competing Risks – Data format


Old method

| PI D | Т | Y1 | Y2 | Tim |
|---------|---|-----------|-----------|-----|
| 1 | 1 | 0 | 0 | 10 |
| 2 | 0 | 0 | 1 | 4 |
| 3 | 0 | 1 | 0 | 2 |

For outcome (Y1, Y2): 0 = censored, 1 = event









Competing Risks – Data format

Competing Risk method

| PI D | Т | Y | Tim e |
|---------|---|---|----------|
| 1 | 1 | 0 | 10 |
| 2 | 0 | 2 | 4 |
| 3 | 0 | 1 | 2 |

For outcome (Y):

0 = censored

1 = event 1 (death from cancer, our primary event)

2 = event 2 (death from CVD, competing event)







Competing Risks – Key Concepts

- Cumulative incidence function (CIF)
 - The cumulative incidence function gives the proportion of patients at time t who have died from cause k accounting for the fact that patients can die from other causes.
- Cause-specific hazard (won't cover today)
 - The cause-specific hazard, $h_k(t)$, is the instantaneous risk of dying from a particular cause k given that the subject is still alive at time t.
- Subdistribution hazard (won't cover today)
 - The subdistribution hazard, $h_{ks}(t)$, is the instantaneous risk of dying from a particular cause k given that the subject has not died from cause k.







Cumulative Incidence Function (CIF)

The cumulative incidence function gives the proportion of patients at time t who have died from cause k accounting for the fact that patients can die from other causes. Define:

- S_t = Number at risk at the end of period t
- E_t = Number of primary events in period t
- A_t = Number of competing events in period t

$$P(E = t \mid E \ge t) \approx \frac{E_t}{E_t + A_t}$$





 $+S_{t}$



Competing Risks

Cumulative Incidence Function (CIF)

 S_t = Number at risk at the end of period t E_t = Number of primary events in period t A_t = Number of competing events in period t

Note:

$$P(E = t \mid E \ge t) \approx \frac{E_t}{E_t + A_t}$$

 $\rightarrow \text{Kaplan-Meier estimator does NOT work !} \\ P(E \ge t+1 \mid E \ge t) \neq 1 - \frac{E_t}{E_t + A_t + S_t}$



 $+S_{t}$

40



Competing Risks

Cumulative Incidence Function (CIF)

Define the survival function as before (using **Kaplan-Meier**)

$$\hat{S}(t) = \prod_{j=1}^{t} \left(1 - \frac{A_j + E_j}{E_j + A_j + S_j} \right) \qquad \hat{S}_0(t) = 1$$

Competing risk method

Old method

Define the **CIF** (of the primary events) as

$$\hat{C}_{E}(t) = \sum_{j=1}^{t} \frac{E_{j}}{E_{j} + A_{j} + S_{j}} \hat{S}(j-1) \qquad \hat{C}(t)$$

Competing risk method

Old method



$\prod_{j=1}^{t} \left(1 - \frac{E_j}{E_j + S_j} \right)$


 $) = \sum_{i=1}^{r} \frac{E_{j}}{E_{j} + S_{j}} \hat{S}_{0}(j-1)$



CIF compared to **Kaplan-Meier**

 $\hat{C}(t) > \hat{C}_E(t)$

So, Kaplan-Meier (old method) overestimates the hazard rate









Competing Risks

- We won't cover more statistical analysis models in the competing risks today, such as Causespecific hazard model and Subdistribution hazard model.
- Keep in mind: When your study subjects are at risk of more than one mutually exclusive event such as death from different causes, Kaplan-Meier estimator may NOT be appropriate. Competing risk methods may be considered.
- Come to BCC for consulting !





Summary

- A common circumstance in working with survival data is that not all the individuals in a sample are observed until their respective times of "failure". The incomplete observation of a times to "failure" is known as censoring;
- Kaplan-Meier method is a nonparametric technique that uses the exact survival time for each individual in a sample instead of group the times into intervals
- A nonparametric technique known as the logrank test is used to determine whether survival differs systematically between the groups.
- Cox proportional hazard regression model is a semi-parametric method to study the effect of different covariates on a time-to-event endpoint after adjusting for each other.
- Competing risks occur when a patient is at risk of more than one mutually exclusive event such as death from different causes. Kaplan-Meier estimator may NOT be appropriate. Competing risk methods may be considered.



References



TEXT BOOKS

1.João Moreira, Andre Carvalho, Tomás Horvath – "A General Introduction to Data Analytics" – Wiley - 2018

2.An Introduction to R, Notes on R: A Programming Environment for Data Analysis and Graphics. W. N. Venables, D.M. Smith and the R Development Core Team. Version 3.0.1 (2013-05-16). URL: https://cran.r-project.org/doc/manuals/r-release/R-intro.pdf **References:**

- 1. Dean J, —Big Data, Data Mining and Machine learning, Wiley publications, 2014.
- 2. Provost F and Fawcett T, —Data Science for Business, O'Reilly Media Inc, 2013.
- 3. Janert PK, —Data Analysis with Open Source Tools, O'Reilly Media Inc, 2011.
- **4. Weiss SM, Indurkhya N and Zhang T,** *—Fundamentals of Predictive Text Mining,* Springer-Verlag London Limited, 2010.

5.Marz N and Warren J,- Big Data, Manning Publications, 2015

Thank You



publications, 2014. ly Media Inc, 2013. Media Inc, 2011. *edictive Text Mining*, Springer-Verlag